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ABSTRACT
Although delayed puberty is relatively common and often familial,
its molecular and pathophysiologic basis is poorly understood. In
contrast, the molecular mechanisms underlying some forms of hy-
pogonadotropic hypogonadism (HH) are clearer, following the de-
scription of mutations in the genes KAL, GNRHR, and PROP1. Mu-
tations in another gene, DAX1 (AHC), cause X-linked adrenal
hypoplasia congenita and HH. Affected boys usually present with
primary adrenal failure in infancy or childhood and HH at the ex-
pected time of puberty.
DAX1 mutations have also been reported to occur with a wider
spectrum of clinical presentations. These cases include female car-
riers of DAX1 mutations with marked pubertal delay and a male with
incomplete HH and mild adrenal insufficiency in adulthood. Given
this emerging phenotypic spectrum of clinical presentation in men
and women with DAX1 mutations, we hypothesized that DAX1 might
be a candidate gene for mutation in patients with idiopathic sporadic
or familial HH or constitutional delay of puberty. Direct sequencing
of DAX1 was performed in 106 patients, including 85 (80 men and 5
women) with sporadic HH or constitutional delay of puberty and
patients from 21 kindreds with familial forms of these disorders. No
DAX1 mutations were found in these groups of patients, although
silent single nucleotide polymorphisms were identified (T114C,
G498A). This study suggests that mutations in DAX1 are unlikely to
be a common cause of HH or pubertal delay in the absence of a
concomitant history of adrenal insufficiency. (J Clin Endocrinol
Metab 84: 4497–4500, 1999)
T
HE ASSOCIATION of DAX1 (AHC) gene mutations
with X-linked adrenal hypoplasia congenita (AHC)
and hypogonadotropic hypogonadism (HH) is well estab-
lished (OMIM: 300200) (1, 2). More than 50 different muta-
tions in the gene encoding DAX-1 have been reported in this
condition (3–6). Affected boys typically present with pri-
mary adrenal insufficiency in infancy or childhood. HH usu-
ally becomes evident later in life with failure of pubertal
development (7, 8).
DAX-1 is an orphan nuclear hormone receptor that is ex-
pressed in the adrenal gland, gonads, hypothalamus, and
pituitary gonadotropes (9). The HH caused by DAX1 mu-
tations seems to involve deficits at both hypothalamic and
pituitary levels (10–13). DAX-1 is also expressed in Sertoli
cells (14), and male Ahch (Dax1) knockout mice have disor-
dered spermatogenesis and infertility (15). DAX-1 has a cru-
cial role, therefore, in the development and function of the
reproductive axis at multiple levels. Different approaches to
counselingandtreatmentareneededforpatientswithDAX1
mutations compared to those with hypothalamic forms of
HH, such as Kallmann syndrome (3, 16).
Recently, DAX1 gene mutations have been found in sev-
eral men and women who have less typical reproductive
phenotypes. These cases include: 1) partial HH in a man who
presented later in life with mild adrenal failure (13); 2) HH,
but normal adrenal function, in a woman who is homozy-
gousforaDAX1mutationthroughgeneconversion(17);and
3) extreme pubertal delay, but normal fertility, among het-
erozygousfemalecarriersofDAX1mutations(12).Giventhe
phenotypic spectrum of reproductive disorders now re-
ported, we hypothesized that DAX1 mutations might cause
idiopathic familial or sporadic HH or constitutional delay of
puberty (CD) among patients lacking a history of overt ad-
renal failure. DNA sequence analysis of over 100 such pa-
tients suggests, however, that coding sequence mutations in
DAX1 are unlikely to be a common cause of such conditions.
Subjects and Methods
Subjects
DAX1 was sequenced directly in 106 patients who had sporadic
(nonfamilial)orfamilialHH(seePatientCharacteristicsfordefinitions)or
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4497CD (testicular volume ,4 mL and delay of sexual maturation at 14 yr
of age). Patients were not recruited if they had multiple pituitary hor-
mone deficiencies or if a likely cause for their altered hypothalamic-
pituitary-gonadal (HPG) function was evident (for example, a history of
tumors, cranial irradiation, or syndromes associated with HH). Muta-
tionsinthegenesencodingtheGnRHreceptorandanosmin-1(KAL)had
been excluded in 75% and 80% of the patients, respectively.
PCR and direct sequencing of DAX1
After obtaining Institutional Review Board approval, DNA was ex-
tracted from patients’ blood leukocytes using standard methods. Both
exons of DAX1, their splice sites, and a 240-bp 59 region of the DAX1
promoter region were PCR amplified using the following six primer
pairs: DAX1.1 For: 59-TGAGACAGGGAAAGGGGTAAT-39; DAX1.1
Rev: 59-CCGGGCTCATCGCCGCACGAA-39; DAX1.2 For: 59-TGGTG-
GATCAGTGTTGGGGC-39; DAX1.2 Rev: 59-CCGGGATCAGAGCCG-
CACGAA-39; DAX1.3 For: 59-AAGCAAACGTACGCGGCAC-39;
DAX1.3 Rev: 59-CCTCTGCGCGAAGTAGGAGC-39; DAX1.4 For: 59-
TAGCTCAAAGCAAACGCACGTG-39; DAX1.4 Rev: 59-GACGC-
CCAGCAGTTGCGCAC-39; DAX1.5 For: 59-GCCTCAGCGGGCCTGT-
TGAAG-39; DAX1.5 Rev: 59-CCCGATGCTTTTGTGAGCTGGGAA-39;
DAX2.1 For: 59-GCTAGCAAAGGACTCTGTGGT-39; DAX2.1 Rev:
59-TGTGTGGCCCACATGACTTTA-39.
PCR conditions were: 1-min predenaturation at 96 C; 35 cycles of 1
min at 94 C, annealing for 1 min at 55–58 C, and extension for 1 min at
72 C; and 15-min elongation at 72 C. Buffer conditions have been de-
scribed previously (18). Direct sequencing was performed in forward
and reverse using dRhodamine (PE Applied Biosystems, Foster City,
CA) or Thermo Sequenase II (Amersham Pharmacia Biotech Pharmacia,
Piscataway,NJ)dyeterminatorsequencingkitsandautomatedsequenc-
ers (Models 373A and 377; PE Applied Biosystems, Foster City, CA).
Results
Patient Characteristics
Patient characteristics are shown in Fig. 1.
Sporadic HH/CD (n 5 85). The majority of patients investi-
gated had sporadic (nonfamilial) reproductive disorders
(n 5 85) (Fig. 1, left). Isolated sporadic HH was present in 83
patients (78 men and 5 women), and CD was present in 2
boys. Of those with HH, seven had an adult-onset form of
HH in which normal pubertal development occurs but HH,
apulsatile LH secretion, and low testosterone develops in
adultlife(19).Anadditionalfourmenhavethefertileeunuch
syndrome. This condition is diagnosed when testicular de-
velopment and spermatogenesis occurs, but systemic testos-
terone concentrations are insufficient for full virilization
(20–22). In the cases of CD, pubertal development was par-
ticularly delayed, as no spontaneous testicular enlargement
or sexual maturation was evident by 15 yr of age.
Familial HH/CD (n 5 21). DAX1 was sequenced in a total of
21 kindreds with familial forms of HH, CD, or both (Fig. 1,
right). Families were excluded if the phenotype appeared to
be inherited from the proband’s father or father’s family, as
this precluded an X-linked gene as the cause of their condi-
tion.Atotalof13ofthe21kindredshadfamilialHHaffecting
both male and female family members. Familial CD with a
classic X-linked pattern of inheritance was present in three
kindreds.Anadditionalninefamilieshadtwoaffectedbroth-
ers in the same generation. In these cases, polymorphic mi-
crosatellite markers in the region of the DAX1 locus
(DXS1202, DXS1214, DXS1226; PE Applied Biosystems) were
used first to determine whether both affected sons inherited
the same X-chromosome from their mother. Common de-
scentofthesamematernalX-allele(DAX1locus)tobothsons
occurred in five of the nine families (two HH/CD, three
CD/CD). Because a common allele segregated with the phe-
notype in these cases, DAX1 was considered a candidate
gene, and direct sequencing was undertaken. In four fami-
lies, however, affected brothers inherited different maternal
X-alleles, making DAX1 an unlikely candidate gene for the
phenotype seen in these cases (four CD/CD). These families
were excluded from further analysis.
Mutational Analysis
Direct sequencing of the coding region, splice sites, and
promoter (2240 bp) of DAX1 did not reveal any mutations
inthe106patientsstudied.Singlenucleotidepolymorphisms
were detected at two sites [T114C and G498A, the A of the
ATG translation initiation codon being designated 11 (23)]
(Table 1). These nucleotide changes did not alter the amino-
acid sequence of DAX-1 (C38C and R166R, respectively) and
were detected at a similar frequency in a control population.
Discussion
Pubertal delay is a common clinical problem that is mul-
tifactorial in its origin. Environmental and nutritional factors
can delay the onset and progression of puberty. A variety of
hormonal disorders and acquired structural defects that af-
fect the HPG axis can affect the process of sexual maturation
(for reviews, see Refs. 24–27). Based on family histories and
twin studies, genetic components also seem to contribute to
the timing of puberty (24, 28). The genetic basis of pubertal
development is poorly understood at present. However, the
coexistence of pubertal delay with variable degrees of HH in
some families suggests that a common factor may be respon-
sible for these phenotypes in a subset of patients with pu-
bertal disorders (29).
FIG. 1. Patient characteristics. The majority of patients studied (n 5
85)hadsporadic(nonfamilial)formsofHHorCD(left).Theremaining
patients (n 5 21) had familial forms of HH or CD (right). A subset of
patients who had an X-linked pattern of familial HH or CD were
screened first using microsatellite markers in the region of the DAX1
(AHC) locus. Sequencing analysis was only undertaken in those fam-
ilies where two affected brothers inherited a common X-allele from
their mother, thus making DAX1 a potential candidate gene for mu-
tation. (m, male; f, female).
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cause HH in humans (30). Affected patients may show a
spectrum of mild to severe phenotypes, even within a kin-
dred with the same mutation. Mutations in these genes may
affect the HPG axis at various levels. For example, mutations
in KAL (anosmin-1) cause the hypothalamic HH observed in
patients with X-linked Kallmann syndrome (31, 32), whereas
mutations in the gene encoding the GnRH receptor (33, 34)
primarily affect gonadotrope function. Mutations in the pi-
tuitarytranscriptionfactorsPROP-1(35)andHESX-1(36)can
also cause HH, although in these cases additional anterior
pituitaryhormonesareaffected.Definingthemolecularbasis
of these reproductive disorders is important because ap-
proaches to treatment and counseling are different. At
present, however, the underlying pathogenesis of most
formsoffamilialorsporadicHH/CDremainsunclear(16,29,
30, 37).
The association of HH with X-linked adrenal hypoplasia
congenita and DAX1 gene mutations is well established.
Although HPG activity may be relatively preserved in in-
fancy (38–40), the majority of affected patients show marked
HH at the expected time of puberty. In rare cases, partial
pubertal development has been observed (5). In this study,
we hypothesized that mutations in DAX1 might be found in
a subset of patients with HH or delayed puberty alone. In
additiontoitsfunctionalcharacteristics,thelocationofDAX1
on the X chromosome makes it an attractive candidate gene
for a relatively common disorder because phenotypic effects
are likely to be manifest in hemizygous males.
We included patients with sporadic as well as familial
disorders in our cohort, as over one third of AHC patients
reported to date have no other affected family members and
they have de novo DAX1 mutations (4, 41, 42). The recent
reportofamanwhofirstpresentedat28yrofagewithpartial
HH, but only mild adrenal failure, demonstrates that a re-
productive phenotype may precede adrenal symptoms in
certain individuals with DAX1 mutations (13). In addition,
several females with sporadic HH were included in this
study following the report of a woman with a homozygous
DAX1 mutation who has HH and normal adrenal function
(17). Finally, we included families in which both males and
females have HH, as extreme pubertal delay has been re-
ported in some female carriers of DAX1 mutations (12). Such
a phenotype in heterozygous women could result from
skewed X-inactivation.
Identifying patients with DAX1 mutations among those
attending clinics for HH is important for a variety of reasons.
First, different approaches to treatment might be needed for
suchpatients,giventheirvariableresponsetoGnRH(10–13).
Although data are limited at present, spermatogenesis may
beaffectedbyDAX1mutationsinhumansasitisinmice(15),
and the response to gonadotropin treatment may be im-
paired (12, 13). Second, these patients may have subclinical
adrenal failure that could become clinically significant if left
undiagnosed, as highlighted by the patient who presented
with increasing symptoms of adrenal insufficiency in his late
twenties (13). Third, when the genetic basis for a disorder is
identified in a proband, appropriate genetic counseling can
be provided to additional family members. In the case of
DAX1 mutations, female carriers of the mutation can be
advised regarding testing of male offspring for adrenal in-
sufficiency. Boys with DAX1 mutations can be given glu-
cocorticoids and mineralocorticoids, as indicated, and hor-
monal replacement can be provided at the time of puberty.
Finally, any mutations found to be associated with a varied
reproductive phenotype could provide important insight
into the structure and function of the DAX-1 protein. The
majority of DAX1 mutations reported to date are frameshift
or nonsense mutations (3, 4). Missense mutations, which
might cause relatively subtle alterations in protein function,
have been rare among the early, classical cases of AHC and
seem to be localized to the putative ligand-binding (carboxy-
terminal) domain of DAX-1 (1, 5, 6, 38, 43–45). A direct
sequencing approach was used, therefore, to optimize our
sensitivity for detecting missense mutations. Although two
previously reported polymorphisms were discovered in a
significant number of patients (4), no DAX1 mutations were
found in the 106 patients studied. These findings indicate
that DAX1 mutations are unlikely to be a significant cause of
HH or pubertal delay in the absence of a personal or family
history of adrenal failure.
References
1. Muscatelli F, Strom TM, Walker AP, et al. 1994 Mutations in the DAX-1 gene
giverisetobothX-linkedadrenalhypoplasiacongenitaandhypogonadotropic
hypogonadism. Nature. 372:672–676.
2. Zanaria E, Muscatelli F, Bardoni B, et al. 1994 An unusual member of the
nuclear hormone receptor superfamily responsible for X-linked adrenal hy-
poplasia congenita. Nature. 372:635–641.
3. Yu RN, Achermann JC, Ito M, Jameson JL. 1998 The role of DAX-1 in re-
production. Trends Endocrinol Metab. 9:169–175.
4. Reutens AT, Achermann JC, Ito M, et al. 1999 Clinical and functional effects
of mutations in the DAX-1 gene in patients with adrenal hypoplasia congenita.
J Clin Endocrinol Metab. 84:504–511.
5. BassettJH,O’HalloranDJ,WilliamsGR,BeardwellCG,ShaletSM,Thakker
RV. 1999 Novel DAX1 mutations in X-linked adrenal hypoplasia congenita
and hypogonadotrophic hypogonadism. Clin Endocrinol. 50:69–75.
6. Abe S, Nakae J, Yasoshima K, et al. 1999 Novel missense mutation
(Leu466Arg) of the DAX1 gene in a patient with X-linked congenital adrenal
hypoplasia. Am J Med Genet. 84:87–89.
7. Prader A, Zachmann M, Illig R. 1975 Luteinizing hormone deficiency in
hereditary congenital adrenal hypoplasia. J Pediatr. 86:421–422.
8. Golden MP, Lippe BM, Kaplan SA. 1977 Congenital adrenal hypoplasia and
hypogonadotropic hypogonadism. Am J Dis Child. 131:1117–1118.
9. Guo W, Burris TP, McCabe ER. 1995 Expression of DAX-1, the gene respon-
sible for X-linked adrenal hypoplasia congenita and hypogonadotropic hy-
pogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis. Biochem
Mol Med. 56:8–13.
10. Habiby RL, Boepple P, Nachtigall L, Sluss PM, Crowley Jr WF, Jameson JL.
1996 Adrenal hypoplasia congenita with hypogonadotropic hypogonadism:
TABLE 1. Single nucleotide polymorphisms in the coding region of DAX1
Nucleotide
polymorphism Codon Males (n 5 95) (%) Females (n 5 11) (%)
T C TT TC CC
T114C C38C 12 (13) 83 (87) 3 (27) 2 (18) 6 (55)
G A GG GA AA
G498A R166R 69 (73) 26 (27) 8 (73) 1 (9) 2 (18)
ANALYSIS OF DAX1 IN HHG/PUBERTAL DELAY 4499evidence that DAX-1 mutations lead to combined hypothalamic and pituitary
defects in gonadotropin production. J Clin Invest. 98:1055–1062.
11. Hamaguchi K, Arikawa M, Yasunaga S, et al. 1998 Novel mutation of the
DAX1 gene in a patient with X-linked adrenal hypoplasia congenita and
hypogonadotropic hypogonadism. Am J Med Genet. 76:62–66.
12. Seminara SB, Achermann JC, Genel M, Jameson JL, Crowley Jr WF. 1999
X-linked adrenal hypoplasia congenita: a mutation in DAX1 expands the
phenotypic spectrum in males and females. J Clin Endocrinol Metab.
84:4501–4509.
13. Tabarin A, Achermann JC, Recan D, et al. 1999 A novel mutation in DAX1
gene responsible for late onset adrenal insufficiency, incomplete hypogonad-
ism and impaired spermatogenesis. Proc 81st Meeting of The Endocrine So-
ciety, San Diego, CA (Abstract P2–154).
14. TamaiKT,MonacoL,AlastaloTP,LalliE,ParvinenM,Sassone-CorsiP.1996
Hormonal and developmental regulation of DAX-1 expression in Sertoli cells.
Mol Endocrinol. 10:1561–1569.
15. Yu RN, Ito M, Saunders TL, Camper SA, Jameson JL. 1998 Role of Ahch in
gonadal development and gametogenesis. Nat Genet. 20:353–357.
16. Seminara SB, Hayes FJ, Crowley Jr WF. 1998 Gonadotropin-releasing hor-
mone deficiency in the human (idiopathic hypogonadotropic hypogonadism
and Kallmann’s syndrome): pathophysiological and genetic considerations.
Endocr Rev. 19:521–539.
17. Merke DP, Tajima T, Baron J, Cutler Jr GB. 1999 Hypogonadotropic hypo-
gonadism in a female caused by an X-linked recessive mutation in the DAX1
gene. N Engl J Med. 340:1248–1252.
18. Ito M, Mori Y, Oiso Y, Saito H. 1991 A single base substitution in the coding
region for neurophysin II associated with familial central diabetes insipidus.
J Clin Invest. 87:725–728.
19. Nachtigall LB, Boepple PA, Pralong FP, Crowley Jr WF. 1997 Adult-onset
idiopathic hypogonadotropic hypogonadism—a treatable form of male infer-
tility. N Engl J Med. 336:410–415.
20. Pasqualini RQ, Bur EG. 1950 Sindrome hipoandrogenico con gametogenesis
conservada: clasificacion de la insuficiencis testicular. Rev Assoc Med Argent.
64:6.
21. McCullagh EP, Beck JC, Scaffenburg CA. 1953 A syndrome of eunuchoidism
with spermatogenesis, normal urinary FSH and low or normal ICSH: “Fertile
Eunuchs”. J Clin Endocrinol Metab. 13:489–509.
22. BoyarRM,FinkelsteinJW,WitkinM,KapenS,WeitzmanE,HellmanL.1973
Studies of endocrine function in “isolated” gonadotropin deficiency. J Clin
Endocrinol Metab. 36:64–72.
23. Antonarakis SE. 1998 Recommendations for a nomenclature system for hu-
man gene mutations. Nomenclature Working Group. Hum Mutat. 11:1–3.
24. Bourguignon JP. 1996 Environmental factors and human puberty. Acta Pae-
diatr Suppl. 417:92–94.
25. Rogol AD. 1998 Leptin and puberty. J Clin Endocrinol Metab. 83:1089–1090.
26. Bradshaw KD, Quigley CA. 1998 Disorders of pubertal development. In:
Jameson JL, ed. Principles of molecular medicine. New Jersey: Humana Press;
569–580.
27. Ferin M. 1999 Stress and the reproductive cycle. J Clin Endocrinol Metab.
84:1768–1774.
28. Pickles A, Pickering K, Simonoff E, Silberg J, Meyer J, Maes H. 1998 Genetic
“clocks” and “soft” events: a twin model for pubertal development and other
recalled sequences of developmental milestones, transitions, or ages at onset.
Behav Genet. 28:243–253.
29. Waldstreicher J, Seminara SB, Jameson JL, et al. 1996 The genetic and clinical
heterogeneity of gonadotropin-releasing hormone deficiency in the human.
J Clin Endocrinol Metab. 81:4388–4395.
30. AchermannJC,JamesonJL.1999Fertilityandinfertility:geneticcontributions
from the hypothalamic-pituitary-gonadal axis. Mol Endocrinol. 13:812–818.
31. Franco B, Guioli S, Pragliola A, et al. 1991 A gene deleted in Kallmann’s
syndrome shares homology with neural cell adhesion and axonal path-finding
molecules. Nature. 353:529–536.
32. Legouis R, Hardelin JP, Levilliers J, et al. 1991 The candidate gene for the
X-linkedKallmannsyndromeencodesaproteinrelatedtoadhesionmolecules.
Cell. 67:423–435.
33. de Roux N, Young J, Misrahi M, et al. 1997 A family with hypogonadotropic
hypogonadism and mutations in the gonadotropin-releasing hormone recep-
tor. N Engl J Med. 337:1597–1602.
34. LaymanLC,CohenDP,JinM,etal.1998Mutationsingonadotropin-releasing
hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet.
18:14–15.
35. Wu W, Cogan JD, Pfaffle RW, et al. 1998 Mutations in PROP1 cause familial
combined pituitary hormone deficiency. Nat Genet. 18:147–149.
36. Dattani MT, Martinez-Barbera JP, Thomas PQ, et al. 1998 Mutations in the
homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human
and mouse. Nat Genet. 19:125–133.
37. Georgopoulos NA, Pralong FP, Seidman CE, Seidman JG, Crowley Jr WF,
Vallejo M. 1997 Genetic heterogeneity evidenced by low incidence of KAL-1
gene mutations in sporadic cases of gonadotropin-releasing hormone defi-
ciency. J Clin Endocrinol Metab. 82:213–217.
38. Takahashi T, Shoji Y, Shoji Y, Haraguchi N, Takahashi I, Takada G. 1997
Active hypothalamic-pituitary-gonadal axis in an infant with X-linked adrenal
hypoplasia congenita. J Pediatr. 130:485–488.
39. Kaiserman KB, Nakamoto JM, Geffner ME, McCabe ER. 1998 Minipuberty
of infancy and adolescent pubertal function in adrenal hypoplasia congenita.
J Pediatr. 133:300–302.
40. Peter M, Viemann M, Partsch CJ, Sippell WG. 1998 Congenital adrenal
hypoplasia: clinical spectrum, experience with hormonal diagnosis and report
on new point mutations of the DAX-1 gene. J Clin Endocrinol Metab.
83:2666–2674.
41. Yanase T, Takayanagi R, Oba K, Nishi Y, Ohe K, Nawata H. 1996 New
mutations of DAX-1 genes in two Japanese patients with X-linked congenital
adrenal hypoplasia and hypogonadotropic hypogonadism. J Clin Endocrinol
Metab. 81:530–535.
42. Kinoshita E, Yoshimoto M, Motomura K, et al. 1997 DAX-1 gene mutations
and deletions in Japanese patients with adrenal hypoplasia congenita and
hypogonadotropic hypogonadism. Horm Res. 48:29–34.
43. Nakae J, Abe S, Tajima T, et al. 1997 Three novel mutations and a de novo
deletion mutation of the DAX-1 gene in patients with X-linked adrenal hy-
poplasia congenita. J Clin Endocrinol Metab. 82:3835–3841.
44. Schwartz M, Blichfeldt S, Muller J. 1997 X-linked adrenal hypoplasia in a
large Greenlandic family. Detection of a missense mutation (N4401) in the
DAX-1 gene; implication for genetic counselling and carrier diagnosis. Hum
Genet. 99:83–7.
45. Zhang YH, Guo W, Wagner RL, et al. 1998 DAX1 mutations map to putative
structural domains in a deduced three-dimensional model. Am J Hum Genet.
62:855–864.
4500 ACHERMANN ET AL. J C E&M² 1999
Vol 84 ² No 12